“That is Poppy,” says Howard Greenwood, proudly displaying me his prize cow. In fact, although, “cow” is charming nuclear analysis slang. Poppy is a slim glass column full of radioactive waste that lives not in a pasture, however in a high-security lab. Greenwood and his group right here at the UK Nationwide Nuclear Laboratory (UKNNL) close to Preston “milk” her for radioactive lead.

Why have interaction on this ticklish enterprise? It’s all to do with the rise of a brand new technology of radioactive medicine which might be displaying enormous promise as most cancers remedies. Radioactivity is hardly new in drugs, however these medicine have a uncommon energy and look set to essentially take off. The one downside is that, in the event that they do, demand for the radioisotopes they embody will vastly outstrip present provides.

Cue a worldwide race to ramp up manufacturing. Some, like Greenwood’s group, are digging by way of stockpiles of nuclear waste and refining it. Others are sifting leftovers from chilly war-era atom-bomb initiatives, or scrounging supplies from disused medical units. It’s a high-stakes endeavour, promising not solely life-saving remedies but in addition probably huge earnings. “We’re actually seeing massive pharma make investments billions in it,” says Sven Van den Berghe, CEO of Belgian isotope-maker PanTera.

The historic alchemists could have been misguided in some ways, however they weren’t fallacious that one aspect can remodel into one other. It occurs naturally, by way of three foremost sorts of radioactive decay. An atomic nucleus can emit a part of itself within the type of both a bundle of protons and neutrons, an electron, or a blast of radiation. These processes, referred to as alpha, beta and gamma decay, respectively, convert the atom into a distinct aspect. Researchers use a unit referred to as half-life to measure how lengthy it takes for 50 per cent of the atoms in a radioactive substance to bear this transition.

The concept of utilizing radioactivity as a remedy dates again to the early 1900s, shortly after Marie Skłodowska Curie and her husband Pierre found the aspect radium. Docs discovered that sealed radium samples, mounted on needles and inserted into sufferers, may shrink tumours with their fierce blast of alpha particles. This therapy, radium brachytherapy, flourished till the Fifties, when radium was deserted in favour of safer isotopes.

The newer buzz round radioactivity in drugs centres on one thing referred to as radioligand remedy. This addresses the well-known downside with radiotherapy: it will probably injury wholesome cells in addition to tumours. The concept is to tether a radioactive atom to a molecule referred to as a ligand that seeks out and binds to most cancers cells. On this manner, the medicine ship a exact strike with fewer unwanted effects.

Radioligands actually received their increase in 2017, when pharmaceutical big Novartis launched a drug referred to as Lutathera, which tethers lutetium-177 to a peptide that targets gastrointestinal most cancers cells. In 2022, the corporate introduced out one other lutetium-177 drug referred to as Pluvicto, which treats prostate most cancers. “They demonstrated that focused radiopharmaceuticals may be developed, authorised, manufactured at scale,” says Sophie Letournel at Orano Med, a French radiopharmaceutical developer.

These two medicine racked up $2.8 billion in gross sales for Novartis in 2025, and now dozens of different pharma corporations desire a piece of the motion. Analysts at Morgan Stanley have predicted this surge in curiosity will assist the worldwide radiopharmaceutical market develop virtually sixfold to $39 billion in gross sales by 2032.

The success of Lutathera and Pluvicto has sparked a speedy build-out of services to supply extra lutetium-177. However already, researchers are enthusiastic about the following technology of radioligand therapies. Lutetium-177 decays by emitting beta particles, and it will probably take a whole lot of those rushing electrons to kill a cell. However, isotopes that produce heavier, slower alpha particles can have the identical deadly impact with simply 10 hits. If betas are like a blast of buckshot, alphas are like a grenade.

Thus, researchers are actually creating radioligand medicine with a number of completely different alpha-emitting isotopes as an alternative (see “The radioactive armoury”). The difficulty is, these alpha emitters are a lot rarer and extra hazardous to supply. So, how are we going to pay money for them?

The world’s most costly materials

The main choice for focused alpha remedy is actinium-225. Actinium is chemically much like lutetium, making it straightforward to hook onto the concentrating on molecules utilized in Lutathera and Pluvicto. Scientific trials of those actinium analogues have already progressed to the ultimate phases. One other attraction is that when actinium-225 decays, it produces a cascade of daughters that collectively emit 4 alpha particles and a few betas, probably boosting its killing energy. Such is the demand for actinium-225, says Van den Berghe, that “it’s typically mentioned to be the costliest materials on the earth”. World manufacturing is lower than 0.1 milligrams per yr; that should improve 1000-fold if the isotope is to deal with a whole lot of hundreds of sufferers per yr, in response to calculations by Richard Zimmermann, a radiopharmaceutical analyst at Chrysalium Consulting in Lalaye, France.

There are three main routes to supply it. Some corporations begin from deserted radium brachytherapy sources, now so prized that the Worldwide Atomic Vitality Company (IAEA) launched a worldwide effort to get better them from waste services and hospital basements. Micrograms of radium may be extracted and purified from every supply after which blasted with protons from a round particle accelerator referred to as a cyclotron, triggering a decay sequence that makes actinium-225.

The second strategy exploits uranium-233. In 1955, the US detonated a bomb primarily based on uranium-233 in Nevada, but it surely was judged a flop. Over the next many years, roughly 2 tonnes of uranium-233 had been saved at Oak Ridge Nationwide Laboratory in Tennessee, the place it has steadily decayed right into a smorgasbord of different parts, together with thorium-229.

Each month, TerraPower Isotopes in Bellevue, Washington, will get a number of hundred milligrams of thorium-229, which decays into actinium-225 and different isotopes. The corporate harvests the actinium-225 every week, and has been transport it to clients since late 2024. At full scale, the system may provide a number of hundred thousand affected person doses per yr, says Scott Claunch, president of TerraPower Isotopes.

Ultimately, although, these thorium reserves may run out. That’s why TerraPower is collaborating with PanTera, which has developed a 3rd manufacturing route that stems again to the radium hype following the Curies’ discovery.

In 1915, Belgian miners found uniquely wealthy deposits of radium and uranium in what’s now the Democratic Republic of the Congo, and began digging. The Shinkolobwe mine despatched hundreds of tonnes of radioactive ore to Belgium and provided many of the uranium used within the Manhattan Mission. In the present day, the remnants of Shinkolobwe’s bounty are stored on the Belgian Nuclear Analysis Centre, together with about 100 grams of pure radium-226, the world’s largest stockpile of the isotope. “With the restoration capabilities that our expertise gives, that’s sufficient to supply about 450,000 doses a yr of actinium-225,” says Van den Berghe.

PanTera’s course of begins by firing an intense electron beam into tantalum sheets. The electrons’ sudden deceleration makes them dump their power as X-rays. “It’s precisely the identical factor as a dental X-ray tube, solely at a lot increased energies,” says Van den Berghe. These X-rays are used to batter a radium-226 goal till the atoms launch a neutron, forming radium-225 that subsequently decays into actinium-225. PanTera is constructing a manufacturing facility in Mol, Belgium, to function this course of at scale, which it expects to be absolutely operational in 2029.

Milking Poppy

Regardless of the thrill about actinium-225, it has some drawbacks. For one, the recoil from alpha decay can jolt the atom from its molecular wrapper, permitting it to float away and probably trigger off-target unwanted effects. “As soon as the primary decay begins, you’ve damaged your hyperlink together with your concentrating on molecule. So that you’re principally free within the physique,” says Glenn Rosenthal, co-founder of Nusano, an isotope firm close to Salt Lake Metropolis, Utah. One other problem is actinium-225’s 10-day half-life, which implies sufferers retain the isotope of their our bodies lengthy after therapy.

For a lot of researchers, lead-212 seems to be like a greater choice. Like actinium-225, its decay chain produces each alpha and beta particles, however its half-life is far shorter, at simply 10 hours, that means that after sufferers have been handled, their radioactivity would fade rapidly.

All of which explains why I’ve discovered myself at UKNNL’s lab, at a web site that handles a whole lot of tonnes of uranium per yr and barely welcomes journalists. After clearing a safety test, I’m handled to a security briefing on the emergency indicators I actually don’t wish to hear throughout my go to. “Poisonous Launch”, a quickly warbling panic name, means I ought to head well for an exit. Even worse, “Criticality” is a sinusoidal scream of doom which means I merely must run as quick as I can.

Security gear and radiation sensors donned, I lastly get to fulfill Poppy, who sits behind a thick metal security defend. Her fodder is extracted from nuclear waste (the group prefers to name it “legacy materials”) saved on the Sellafield nuclear web site in Cumbria, which incorporates uranium-232. This isotope has spent many years decaying into thorium-228, and that’s what Greenwood’s group is after. When the researchers feed Poppy with a yellow answer of waste, a particular resin grabs the thorium atoms, permitting uranium and different parts to move. As soon as absolutely loaded, Poppy incorporates a number of nanograms of thorium-228, which finally decays into the coveted lead-212.

Researchers “milk” the collected lead-212 each few days by washing Poppy with dilute acid. They count on to ship the primary batch to drug researchers in Could. The researchers will check whether or not the isotope may be reliably linked to varied concentrating on molecules. “There’s such a buzz about getting this to the stage the place it will probably have a medical profit,” says Laura Maray, a analysis technologist on the group. About 10 lead-212-based medicine are in scientific testing, with extra on the horizon. A number of of those trials depend upon lead-212 provided by Orano Med, which has its personal course of for harvesting the isotope from a 22,000-drum stockpile of French nuclear waste.

In the meantime, corporations with out entry to such sizeable reserves hope to make lead-212 and different isotopes utilizing compact fusion techniques. Huge fusion-power initiatives, equivalent to ITER in France, goal to generate power, however in Bristol, UK, Astral Programs is extra fascinated about utilizing the neutrons launched by fusion to kind helpful isotopes. Earlier compact fusion units haven’t produced a excessive sufficient focus of neutrons to allow economical isotope manufacturing, however Astral has developed a high-voltage fusor that helps generate much more. “All of it comes right down to the economics of price per neutron,” says Astral’s Tom Haywood. The corporate goals to make a variety of isotopes, together with lead-212, which can depend upon radium-226 targets, and expects to have samples prepared for purchasers within the subsequent few years.

Different researchers are a curveball choice. Astatine is in a gaggle of parts referred to as the halogens, and its chemistry is starkly completely different from that of lead or actinium, that are each metals. Which means reasonably than being hugged by a particular molecular wrapper, astatine may very well be immediately hooked up to a drug molecule by a single chemical bond. In precept, a few of these astatine-based medicine may very well be able to crossing the blood-brain barrier, making them well-suited to treating mind tumours.

Astatine-211 has a half-life of simply 7 hours, so it have to be produced moderately near therapy centres, however that additionally limits sufferers’ radiation publicity. Its decay chains contain just one alpha emission, so it would pack much less of a punch than actinium 225, however that might additionally minimise off-target unwanted effects.

The primary path to astatine-211 makes use of a cyclotron to fireside alpha particles into atoms of bismuth, however these techniques typically produce modest quantities of the isotope. To scale up, Nusano has created a 60-kilovolt ionisation chamber that produces way more high-energy alphas than a standard cyclotron. These alphas are accelerated, marshalled into pulses and funnelled in direction of a dozen targets. Nusano’s alpha supply is up and operating, and its accelerator ought to come on-line inside the subsequent few months. “We’ll get extra astatine than all the opposite services on the earth mixed,” says Rosenthal.

We are going to quickly know whether or not the billions invested in all these isotope factories will repay. “We consider that a number of compounds may probably be authorised by 2030,” says TerraPower’s Claunch. “That yr goes to be actually essential to the trade.” In the meantime, again at UKNNL, we end our tour in a cavernous hangar full of big mixing vessels and barrels of chemical compounds, which serves as a pilot plant for processes involving radioactive supplies. In precept, this area may produce sufficient lead-212 to deal with hundreds of sufferers per yr, and Greenwood is raring to go. “We may begin designing a plant tomorrow,” he says.

He concedes it’ll most likely be a number of years earlier than lead-212 from cows like Poppy is utilized in scientific checks. However he’s assured that this remedy will change into a actuality – and he’s powerfully motivated to make it work. “Everybody is aware of somebody who has been affected by most cancers. A good friend of mine died of a form of most cancers that this might have stopped,” he says. “We’ve the individuals, the abilities and the equipment to do that.”